GELS vs ZTS Stock Comparison

Gelteq and Zoetis Prices as of Oct 23, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.43 -28.3% 1M -69.1% 1Y
Market cap
$4.26M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
ZTS Zoetis Inc.
$80.99 +13.1% 1M -44.7% 1Y
Market cap
$33.78B
P/E
12.9x
Revenue (TTM)
$9.52B
Div. yield
0.03%
Animal Health Healthcare
3 wins

Head to Head

3 decided of 12

Zoetis leads on 3 of the 12 questions below (Zoetis 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSZTSLeader
Larger companyMarket capitalisation $4.26M $33.78B ZTS
Cheaper on earningsLower P/E, profitable companies only — 12.9x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 13.8x –
Faster revenue growthRevenue growth, trailing twelve months — +1.5% –
More profitableNet margin, trailing twelve months — 27.5% –
Better return on capitalReturn on invested capital — 23.4% –
Less leveragedLower net debt / EBITDA — 1.8x –
Higher dividend yieldTrailing dividend yield 0.00% 0.03% –
Better 1-year returnPrice return, last 12 months -69.1% -44.7% ZTS
Better 5-year returnAnnualised price return, 5 years — -17.2%/yr –
Less volatileAnnualised volatility, 1 year 159.8% 40.5% ZTS
Higher overall scoreMean of the five percentile scores vs peers — 71/100 –

Percentile Scorecard

GELSZTS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSZTS
Valuation – 88 #79 of 624
Growth – 51 #295 of 603
Profitability – 96 #22 of 555
Financial Health 67 #5 of 13 33 #439 of 657
Shareholder Returns – 89 #41 of 370
Overall – 71
  • GELS ranked among 13 companies in Pharma Services
  • ZTS ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSZTSSPY
1 month -28.3%+13.1% -1.0%
3 months -38.6%+7.5% +2.9%
6 months -38.5%-30.7% +6.4%
Year to date -46.3%-35.6% +11.4%
1 year -69.1%-44.7% +13.1%
3 years —-51.5% +79.4%
3 years, per year —-21.5% +21.5%
5 years —-61.2% +67.7%
5 years, per year —-17.2% +10.9%
10 years —+59.0% +255.2%
10 years, per year —+4.7% +13.5%

Risk

MeasureGELSZTSSPY
Volatility, 1Y 159.8%40.5% 12.7%
Downside volatility, 1Y 122.1%49.2% 12.7%
Beta vs S&P 500, 1Y 1.960.53 1.00
Return / volatility, 1Y -0.43-1.10 1.03
Max drawdown, 5Y -91.9%-72.0% -25.4%
From 52-week high -71.9%-45.1% -2.5%
52-week high $1.53$147.53 $779.14
52-week low $0.39$69.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSZTS
P/E now vs peer median —median 36.1x 12.9xmedian 17.2x
P/S now vs peer median —median 2.7x 3.5xmedian 8.8x
EV/EBITDA now vs peer median —median 37.4x 10.1xmedian 16.0x
P/FCF now vs peer median -6.5xmedian 21.1x 14.5xmedian 17.8x
P/B now vs peer median 0.5xmedian 2.9x 10.7xmedian 2.1x
PEG now vs peer median —median 2.05 1.37median 0.32

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSZTS
Revenue – $9.52B
Gross profit – $6.81B
Operating income – $3.59B
Net income – $2.62B
Free cash flow – $2.32B
R&D – $722.00M
EPS (diluted) – $6.26
Cash & equivalents $6.26K $1.48B
Total debt $8.91M $34.20B
Shares (diluted) 9.27M 417.70M
Enterprise value $2.12M $25.62B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSZTS
P/E – 12.9x
P/FCF -6.5x 14.5x
P/Operating cash flow – 11.8x
P/S – 3.5x
P/B 0.5x 10.7x
P/Tangible book -1.3x 15.0x
EV/EBITDA – 10.1x
EV/EBIT – 11.4x
EV/Revenue – 4.3x
EV/FCF – 17.7x
EV/Operating cash flow – 14.4x
PEG (3Y EPS CAGR) – 1.37

Growth

14 metrics
MetricGELSZTS
Revenue growth (1Y) – 1.5%
Revenue CAGR (3Y) – 5.0%
Gross profit growth (1Y) – 1.8%
Gross profit CAGR (3Y) – 5.7%
Operating income growth (1Y) – -0.1%
Operating income CAGR (3Y) – 5.2%
Net income growth (1Y) – 0.6%
Net income CAGR (3Y) – 5.7%
EPS growth (1Y) – 7.7%
EPS CAGR (3Y) – 9.4%
Operating cash flow growth (1Y) – -4.6%
Operating cash flow CAGR (3Y) – 12.4%
Free cash flow growth (1Y) – 2.1%
Free cash flow CAGR (3Y) – 21.7%

Profitability

14 metrics
MetricGELSZTS
Gross margin – 71.5%
EBITDA margin – 42.8%
Operating margin – 37.7%
Pretax margin – 34.4%
Net margin – 27.5%
FCF margin – 24.3%
Operating cash flow margin – 29.8%
Return on equity – 82.0%
Return on assets – 17.3%
Return on invested capital – 23.4%
Return on capital employed – 27.5%
Asset turnover – 0.6x
Cash conversion (OCF / net income) – 1.1x
Stock comp / revenue – 1.0%

Financial Health

11 metrics
MetricGELSZTS
Debt / assets 0.1% 60.0%
Debt / equity 0.0x 2.9x
Net debt / EBITDA – 1.8x
Debt / FCF – 3.9x
Liabilities / assets 29.4% 79.1%
Equity / assets 70.6% 20.9%
Interest coverage – 15.1x
Current ratio 0.1x 3.1x
Quick ratio 0.1x 1.6x
Cash ratio 0.0x 0.8x
Altman Z-score – 4.81

Shareholder Returns

7 metrics
MetricGELSZTS
Dividend yield – 2.6%
Net buyback yield – 10.9%
Shareholder yield – 13.4%
Payout ratio (earnings) – 34.0%
Payout ratio (FCF) – 38.4%
Dividend growth (1Y) – 6.1%
Dividend CAGR (3Y) – 10.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSZTS
Forward P/E – 13.8xFY2026
EPS, next fiscal year – $5.86FY2026
EPS growth, next FY – -8.6%FY2026
EPS growth, the year after – +13.5%
Revenue, next fiscal year – $9.56BFY2026
Revenue growth, next FY – +0.9%FY2026
Revenue growth, the year after – -7.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSZTS
Held by institutions – 94.7%
Institutions holding – 1,417
Change in shares held, QoQ – -2.6%
Institutions buying – 674
Institutions selling – 582
Buyers to sellers – 1.16

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSZTS
GELS 1.00 0.04
ZTS 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS and ZTS?

Zoetis (ZTS) is the largest by market capitalisation: Gelteq (GELS) $4.26M, Zoetis (ZTS) $33.78B.

Which stock has performed better?

Over the past year Zoetis (ZTS) returned the most: Gelteq (GELS) -69.1%, Zoetis (ZTS) -44.7%. Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Gelteq (GELS) 0.00%, Zoetis (ZTS) 0.03%. Gelteq (GELS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Zoetis (ZTS) has been the steadiest (Gelteq (GELS) 159.8%, Zoetis (ZTS) 40.5%). Volatility measures how widely the price swings, not the risk of the business.

Do GELS and ZTS move together?

Their daily returns over the past year have a correlation of 0.04, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, GELS and ZTS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.